Treatment of cancer with TOR kinase inhibitors

• US 9,937,170 B2
• Filed: 09/27/2016
• Issued: 04/10/2018
• Est. Priority Date: 10/19/2011
• Status: Active Grant

• Current Assignee: Signal Pharmaceuticals, LLC (Bristol-Myers Squibb Company)
• Original Assignee: Signal Pharmaceuticals, LLC (Bristol-Myers Squibb Company)
• Inventors: Xu, Shuichan, Hege, Kristen Mae, Lopez-Girona, Antonia, Raymon, Heather, Narla, Rama K., Chopra, Rajesh
• Primary Examiner(s): Klinkel, Kortney L.
• Assistant Examiner(s): Strong, Tori
• Application Number:
  US15/277,285
• Publication Number:
  US 20170027932A1
• Time in Patent Office: 560 Days
• Field of Search: None
• CPC Class Codes: A61K 31/4166 having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• CPC Class Codes: A61K 31/4188 condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 473/00 Heterocyclic compounds containing purine ring systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 498/04 Ortho-condensed systems

Abstract

Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

Claims

1. A method for achieving complete response, partial response or stable disease, as determined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in a patient having a solid tumor, comprising administering to said patient an effective amount of

7-(6-(2-hydroxypropan-2-yl)pyridine-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

said solid tumor is rapamycin resistant non-small cell lung cancer or rapacymin resistant breast cancer.

2. The method of claim 1, wherein the solid tumor is an advanced solid tumor.

3. The method of claim 1, wherein the solid tumor is non-small cell lung cancer.

4. The method of claim 1, wherein the solid tumor is breast cancer.

5. The method of claim 4, wherein the breast cancer is ER+/Her2, ER+/Her2+, ER-/Her2+or triple negative (TN).